Search for other papers by Laura J Reid in
Google Scholar
PubMed
Search for other papers by Bala Muthukrishnan in
Google Scholar
PubMed
Search for other papers by Dilip Patel in
Google Scholar
PubMed
Search for other papers by Mike S Crane in
Google Scholar
PubMed
Search for other papers by Murat Akyol in
Google Scholar
PubMed
Search for other papers by Andrew Thomson in
Google Scholar
PubMed
Centre for Cardiovascular Science, Queen’s Medical Research Unit, University of Edinburgh, Edinburgh, UK
Search for other papers by Jonathan R Seckl in
Google Scholar
PubMed
Search for other papers by Fraser W Gibb in
Google Scholar
PubMed
Introduction Primary hyperparathyroidism (PHPT) is a common endocrine condition with a prevalence of 0.1–1%, a female preponderance and a strong association with ageing ( 1 , 2 ). In the modern era, PHPT is often detected incidentally through
Search for other papers by Anne M Drewes in
Google Scholar
PubMed
Search for other papers by Maria E Møller in
Google Scholar
PubMed
Search for other papers by Rasmus Hertzum-Larsen in
Google Scholar
PubMed
Search for other papers by Gerda Engholm in
Google Scholar
PubMed
Search for other papers by Hans H Storm in
Google Scholar
PubMed
. An analysis from United States Surveillance, Epidemiology, and End Results Program (SEER) on data from 1993–2000 showed that women diagnosed with breast cancer before the age of 40 had an increased risk of a new primary brain tumour (O/E: 1.80 ( Table
Search for other papers by Lu Yang in
Google Scholar
PubMed
Search for other papers by Xingguo Jing in
Google Scholar
PubMed
Search for other papers by Hua Pang in
Google Scholar
PubMed
Search for other papers by Lili Guan in
Google Scholar
PubMed
Search for other papers by Mengdan Li in
Google Scholar
PubMed
Introduction Primary hyperparathyroidism (PHPT) was originally identified approximately 90 years ago ( 1 ). It is the third-most prevalent endocrine illness and the most common cause of hypercalcemia in patients. The vast majority of cases are
Search for other papers by Luchuan Li in
Google Scholar
PubMed
Search for other papers by Baoyuan Li in
Google Scholar
PubMed
Search for other papers by Bin Lv in
Google Scholar
PubMed
Search for other papers by Weili Liang in
Google Scholar
PubMed
Search for other papers by Binbin Zhang in
Google Scholar
PubMed
Search for other papers by Qingdong Zeng in
Google Scholar
PubMed
Search for other papers by Andrew G Turner in
Google Scholar
PubMed
Search for other papers by Lei Sheng in
Google Scholar
PubMed
Introduction Primary hyperparathyroidism (PHPT) is a common endocrine disorder, having a prevalence of 0.04–0.1% in the general population ( 1 ). The principal role of parathyroid hormone (PTH) is to maintain (raise) blood calcium levels in
Armed Forces College of Medicine, Cairo, Egypt
Search for other papers by Wafaa M Rashed in
Google Scholar
PubMed
Search for other papers by Anas Saad in
Google Scholar
PubMed
Search for other papers by Muneer Al-Husseini in
Google Scholar
PubMed
Search for other papers by Ahmed Mahmoud Galal in
Google Scholar
PubMed
Search for other papers by Assem Mohamed Ismael in
Google Scholar
PubMed
Search for other papers by Ahmed M Al-Tayep in
Google Scholar
PubMed
Search for other papers by Ayman El Shafie in
Google Scholar
PubMed
Search for other papers by Mahmoud Ahmed Ali in
Google Scholar
PubMed
Search for other papers by Ahmad Samir Alfaar in
Google Scholar
PubMed
Introduction The adrenal gland malignancies are extremely sporadic and heterogeneous. It represents 3.6% of endocrine glands cancers ( 1 ). Adrenal malignancies can be either primary adrenal tumors or secondary metastases, with metastases
Search for other papers by Victor Jing-Wei Kang in
Google Scholar
PubMed
Search for other papers by Bo-Ching Lee in
Google Scholar
PubMed
Search for other papers by Jia-Zheng Huang in
Google Scholar
PubMed
Search for other papers by Vin-Cent Wu in
Google Scholar
PubMed
Search for other papers by Yen-Hung Lin in
Google Scholar
PubMed
Search for other papers by Chin-Chen Chang in
Google Scholar
PubMed
Search for other papers by TAIPAI group in
Google Scholar
PubMed
Introduction Primary aldosteronism (PA) is the most common cause of secondary hypertension; approximately 5–10% of hypertensive patients may have PA ( 1 ). However, the incidence of PA may be as high as 20% in patients with treatment
Search for other papers by Cheng Han Ng in
Google Scholar
PubMed
Search for other papers by Yip Han Chin in
Google Scholar
PubMed
Search for other papers by Marcus Hon Qin Tan in
Google Scholar
PubMed
Search for other papers by Jun Xuan Ng in
Google Scholar
PubMed
Department of Medicine, National University Hospital, Singapore
Search for other papers by Samantha Peiling Yang in
Google Scholar
PubMed
Search for other papers by Jolene Jiayu Kiew in
Google Scholar
PubMed
Department of Medicine, National University Hospital, Singapore
Search for other papers by Chin Meng Khoo in
Google Scholar
PubMed
Introduction Primary hyperparathyroidism (PHPT) is a common endocrine disorder that is caused by excessive or inappropriate parathyroid hormone (PTH) secretion with simultaneous derangement of both phosphate and calcium metabolism. PHPT is
Department of Medicine, University of Helsinki, Helsinki University Central Hospital, Helsinki, Finland
Search for other papers by Selina Mäkinen in
Google Scholar
PubMed
Department of Medicine, University of Helsinki, Helsinki University Central Hospital, Helsinki, Finland
Search for other papers by Neeta Datta in
Google Scholar
PubMed
Department of Medicine, University of Helsinki, Helsinki University Central Hospital, Helsinki, Finland
Search for other papers by Yen H Nguyen in
Google Scholar
PubMed
Department of Medicine, University of Helsinki, Helsinki University Central Hospital, Helsinki, Finland
Search for other papers by Petro Kyrylenko in
Google Scholar
PubMed
Search for other papers by Markku Laakso in
Google Scholar
PubMed
Department of Medicine, University of Helsinki, Helsinki University Central Hospital, Helsinki, Finland
Search for other papers by Heikki A Koistinen in
Google Scholar
PubMed
Introduction HMG-CoA reductase inhibitors, statins, lower cholesterol levels by inhibiting mevalonate formation, the rate-limiting step in the cholesterol biosynthesis ( 1 ). These drugs are widely used and effective in primary ( 2 , 3 ) and
Search for other papers by Marieke Stientje Velema in
Google Scholar
PubMed
Search for other papers by Aline de Nooijer in
Google Scholar
PubMed
Search for other papers by Ad R M M Hermus in
Google Scholar
PubMed
Search for other papers by Henri J L M Timmers in
Google Scholar
PubMed
Department of Internal Medicine III, University Hospital Carl Gustav Carus at the Technical University Dresden, Dresden, Germany
Search for other papers by Jacques W M Lenders in
Google Scholar
PubMed
Search for other papers by Olga Husson in
Google Scholar
PubMed
Department of Internal Medicine III, University Hospital Carl Gustav Carus at the Technical University Dresden, Dresden, Germany
Search for other papers by Jaap Deinum in
Google Scholar
PubMed
Introduction Primary aldosteronism (PA) is a common cause of hypertension, accounting for 5–15% of hypertensive patients ( 1 , 2 , 3 ). PA is categorized in an aldosterone-producing adenoma (APA) or bilateral adrenal hyperplasia (BAH). When
Search for other papers by Natacha Driessens in
Google Scholar
PubMed
Search for other papers by Madhu Prasai in
Google Scholar
PubMed
Search for other papers by Orsalia Alexopoulou in
Google Scholar
PubMed
Search for other papers by Christophe De Block in
Google Scholar
PubMed
Search for other papers by Eva Van Caenegem in
Google Scholar
PubMed
Search for other papers by Guy T’Sjoen in
Google Scholar
PubMed
Search for other papers by Frank Nobels in
Google Scholar
PubMed
Search for other papers by Christophe Ghys in
Google Scholar
PubMed
Search for other papers by Laurent Vroonen in
Google Scholar
PubMed
Search for other papers by Corinne Jonas in
Google Scholar
PubMed
Search for other papers by Bernard Corvilain in
Google Scholar
PubMed
Search for other papers by Dominique Maiter in
Google Scholar
PubMed
Introduction Primary adrenal insufficiency (PAI) is a rare disease, most commonly of auto-immune origin. There is a global variation in prevalence from 80 to 145 per million in Europe, with the highest case numbers reported in Scandinavian